Your browser doesn't support javascript.
loading
Incidence and predictors of hepatocellular carcinoma in patients with autoimmune hepatitis.
Colapietro, Francesca; Maisonneuve, Patrick; Lytvyak, Ellina; Beuers, Ulrich; Verdonk, Robert C; van der Meer, Adriaan J; van Hoek, Bart; Kuiken, Sjoerd D; Brouwer, Johannes T; Muratori, Paolo; Aghemo, Alessio; Carella, Francesco; van den Berg, Ad P; Zachou, Kalliopi; Dalekos, George N; Di Zeo-Sánchez, Daniel E; Robles, Mercedes; Andrade, Raul J; Montano-Loza, Aldo J; van den Brand, Floris F; Slooter, Charlotte D; Macedo, Guilherme; Liberal, Rodrigo; de Boer, Ynto S; Lleo, Ana.
Afiliação
  • Colapietro F; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Maisonneuve P; Division of Epidemiology and Biostatistics, IEO European Institute of Oncology IRCCS, Milan, Italy.
  • Lytvyak E; Department of Medicine, Division of Preventive Medicine, University of Alberta, Edmonton, Alberta, Canada.
  • Beuers U; Department of Gastroenterology and Hepatology, Amsterdam UMC, Location AMC, Amsterdam, the Netherlands.
  • Verdonk RC; Department of Gastroenterology and Hepatology, St Antonius Hospital, Nieuwegein, The Netherlands.
  • van der Meer AJ; Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, the Netherlands.
  • van Hoek B; Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands.
  • Kuiken SD; Department of Gastroenterology and Hepatology, OLVG, Amsterdam, the Netherlands.
  • Brouwer JT; Reinier de Graaf Medical Center, Delft, the Netherlands.
  • Muratori P; Division of Internal Medicine, Morgagni-Pierantoni Hospital, Forlì 47100, Italy; Department of Science for the Quality of Life, University of Bologna, Bologna, Italy.
  • Aghemo A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • Carella F; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  • van den Berg AP; University Medical Center Groningen, University of Groningen, the Netherlands.
  • Zachou K; Department of Medicine and Research, Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, 41110, Larissa, Greece.
  • Dalekos GN; Department of Medicine and Research, Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, 41110, Larissa, Greece.
  • Di Zeo-Sánchez DE; Liver Unit, Vírgen de Victoria University Hospital-IBIMA, University of Málaga, CIBERehd, Malaga, Spain.
  • Robles M; Liver Unit, Vírgen de Victoria University Hospital-IBIMA, University of Málaga, CIBERehd, Malaga, Spain.
  • Andrade RJ; Liver Unit, Vírgen de Victoria University Hospital-IBIMA, University of Málaga, CIBERehd, Malaga, Spain.
  • Montano-Loza AJ; Department of Medicine, Division of Gastroenterology and Liver Unit, University of Alberta, Edmonton, Alberta, Canada.
  • van den Brand FF; Department of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Slooter CD; Department of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Macedo G; Department of Gastroenterology and Hepatology, Centro Hospitalar São João, Porto, Portugal.
  • Liberal R; Department of Gastroenterology and Hepatology, Centro Hospitalar São João, Porto, Portugal.
  • de Boer YS; Department of Gastroenterology and Hepatology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands.
  • Lleo A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy; Division of Internal Medicine and Hepatology, Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy. Electronic address: ana.lleo@humanitas.it.
J Hepatol ; 80(1): 53-61, 2024 01.
Article em En | MEDLINE | ID: mdl-37802188
BACKGROUND AND AIMS: Autoimmune hepatitis (AIH) is a rare chronic liver disease of unknown aetiology; the risk of hepatocellular carcinoma (HCC) remains unclear and risk factors are not well-defined. We aimed to investigate the risk of HCC across a multicentre AIH cohort and to identify predictive factors. METHODS: We performed a retrospective, observational, multicentric study of patients included in the International Autoimmune Hepatitis Group Retrospective Registry. The assessed clinical outcomes were HCC development, liver transplantation, and death. Fine and Gray regression analysis stratified by centre was applied to determine the effects of individual covariates; the cumulative incidence of HCC was estimated using the competing risk method with death as a competing risk. RESULTS: A total of 1,428 patients diagnosed with AIH from 1980 to 2020 from 22 eligible centres across Europe and Canada were included, with a median follow-up of 11.1 years (interquartile range 5.2-15.9). Two hundred and ninety-three (20.5%) patients had cirrhosis at diagnosis. During follow-up, 24 patients developed HCC (1.7%), an incidence rate of 1.44 cases/1,000 patient-years; the cumulative incidence of HCC increased over time (0.6% at 5 years, 0.9% at 10 years, 2.7% at 20 years, and 6.6% at 30 years of follow-up). Patients who developed cirrhosis during follow-up had a significantly higher incidence of HCC. The cumulative incidence of HCC was 2.6%, 4.6%, 5.6% and 6.6% at 5, 10, 15, and 20 years after the development of cirrhosis, respectively. Obesity (hazard ratio [HR] 2.94, p = 0.04), cirrhosis (HR 3.17, p = 0.01), and AIH/PSC variant syndrome (HR 5.18, p = 0.007) at baseline were independent risk factors for HCC development. CONCLUSIONS: HCC incidence in AIH is low even after cirrhosis development and is associated with risk factors including obesity, cirrhosis, and AIH/PSC variant syndrome. IMPACT AND IMPLICATIONS: The risk of developing hepatocellular carcinoma (HCC) in individuals with autoimmune hepatitis (AIH) seems to be lower than for other aetiologies of chronic liver disease. Yet, solid data for this specific patient group remain elusive, given that most of the existing evidence comes from small, single-centre studies. In our study, we found that HCC incidence in patients with AIH is low even after the onset of cirrhosis. Additionally, factors such as advanced age, obesity, cirrhosis, alcohol consumption, and the presence of the AIH/PSC variant syndrome at the time of AIH diagnosis are linked to a higher risk of HCC. Based on these findings, there seems to be merit in adopting a specialized HCC monitoring programme for patients with AIH based on their individual risk factors.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Hepatite Autoimune / Neoplasias Hepáticas Tipo de estudo: Clinical_trials / Incidence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Hepatite Autoimune / Neoplasias Hepáticas Tipo de estudo: Clinical_trials / Incidence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article